Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.

Guidelines recommend combined therapy of glucocorticoid and cyclophosphamide (CYC) for patients with idiopathic membranous nephropathy (IMN), while it is associated with severe adverse effects. We conducted a retrospective study to evaluate the effectiveness and safety of glucocorticoid plus tacrolimus (TAC) for IMN. Two hundred and three kidney-biopsy-proven IMN patients were enrolled in this study. One group ( = 142) received glucocorticoid combined with intravenous CYC (750 mg/m body surface) and the other group ( = 61) received glucocorticoid combined with oral TAC (target blood concentration of 4-8 ng/mL). The primary outcomes were achievement of remission and incidence of adverse events. The secondary end points included relapse rates, 24 h urinary protein (UP), serum albumin, serum creatinine and estimated glomerular filtration rate. Over the 18-month observation period, the study suggested that the remission rates at the first 3 months were significantly higher in TAC group than in CYC group (72.1% versus 54.9%,  < .05). Although the cumulative incidence of serious and non-serious adverse events was not different significantly between the two groups, the incidence after first 3 months was lower in TAC group. 24hUP and serum albumin improved in TAC group more than the CYC group ( < .05) over the observed period. Because of its short-term effectiveness and long-term safety profile, glucocorticoid plus TAC might be a better option for IMN.